Karyopharm Therapeutics Inc (KPTI) CEO Sells $91,600.00 in Stock

Karyopharm Therapeutics Inc (NASDAQ:KPTI) CEO Michael Kauffman sold 10,000 shares of the company’s stock in a transaction on Monday, December 18th. The stock was sold at an average price of $9.16, for a total value of $91,600.00. Following the completion of the sale, the chief executive officer now owns 522,143 shares of the company’s stock, valued at $4,782,829.88. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Shares of Karyopharm Therapeutics Inc (KPTI) traded up $0.26 during mid-day trading on Friday, hitting $10.78. The stock had a trading volume of 196,471 shares, compared to its average volume of 185,015. The firm has a market capitalization of $496.34, a price-to-earnings ratio of -4.07 and a beta of 4.09. Karyopharm Therapeutics Inc has a fifty-two week low of $7.48 and a fifty-two week high of $14.63.

Karyopharm Therapeutics (NASDAQ:KPTI) last issued its earnings results on Thursday, November 2nd. The company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.01). Karyopharm Therapeutics had a negative return on equity of 76.83% and a negative net margin of 67,267.47%. research analysts predict that Karyopharm Therapeutics Inc will post -2.58 earnings per share for the current year.

Several research analysts have recently commented on KPTI shares. Cantor Fitzgerald reissued a “buy” rating and issued a $18.00 price target on shares of Karyopharm Therapeutics in a research report on Wednesday, September 20th. Jefferies Group reaffirmed a “buy” rating on shares of Karyopharm Therapeutics in a research report on Friday, October 13th. Royal Bank of Canada reaffirmed a “buy” rating and set a $14.00 target price on shares of Karyopharm Therapeutics in a research report on Wednesday, October 18th. Robert W. Baird reaffirmed a “buy” rating on shares of Karyopharm Therapeutics in a research report on Friday, November 3rd. Finally, Zacks Investment Research lowered Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, November 7th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $17.33.

Several institutional investors and hedge funds have recently modified their holdings of KPTI. Vanguard Group Inc. boosted its position in Karyopharm Therapeutics by 9.8% during the first quarter. Vanguard Group Inc. now owns 1,236,762 shares of the company’s stock worth $15,880,000 after purchasing an additional 110,093 shares in the last quarter. Geode Capital Management LLC boosted its position in Karyopharm Therapeutics by 7.8% during the first quarter. Geode Capital Management LLC now owns 168,770 shares of the company’s stock worth $2,167,000 after purchasing an additional 12,277 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in Karyopharm Therapeutics by 5.7% during the first quarter. Dimensional Fund Advisors LP now owns 275,972 shares of the company’s stock worth $3,543,000 after purchasing an additional 14,917 shares in the last quarter. Schwab Charles Investment Management Inc. boosted its position in Karyopharm Therapeutics by 4.5% during the first quarter. Schwab Charles Investment Management Inc. now owns 86,514 shares of the company’s stock worth $1,111,000 after purchasing an additional 3,762 shares in the last quarter. Finally, Bank of America Corp DE boosted its position in Karyopharm Therapeutics by 0.7% during the first quarter. Bank of America Corp DE now owns 46,127 shares of the company’s stock worth $592,000 after purchasing an additional 308 shares in the last quarter. Hedge funds and other institutional investors own 60.92% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Karyopharm Therapeutics Inc (KPTI) CEO Sells $91,600.00 in Stock” was reported by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are viewing this piece of content on another website, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The correct version of this piece of content can be accessed at https://www.thelincolnianonline.com/2018/01/13/michael-kauffman-sells-10000-shares-of-karyopharm-therapeutics-inc-kpti-stock-updated-updated-updated.html.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.

Insider Buying and Selling by Quarter for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply